“The existing situation has uncovered some structural weaknesses from the EU’s medicines source chain and also a substantial dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides claimed. She advised that supply chain difficulties be dealt with within an EU pharmaceutical system expected for being int… Read More